Study #2023-0627
Phase II study assessing the clinical activity and safety of Brexucabtagene autoleucel as a consolidation in patients with relapsed/refractory (R/R) and newly diagnosed B-cell acute lymphocytic leukemia (ALL) post cytoreductive therapy
MD Anderson Study Status
Enrolling
Treatment Agent
Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD, Mini-hyper-CVD
Description
To learn about the safety of giving the drug brexucabtagene autoleucel to participants with relapsed/refractory B-cell ALL after treatment with inotuzumab ozogamicin, blinatumomab, and either hyper-CVAD or mini-hyper-CVD. Also, to learn if giving brexucabtagene autoleucel to patients with relapsed/refractory or high-risk, newly diagnosed B-cell ALL after treatment with inotuzumab ozogamicin, blinatumomab, and either hyper-CVAD or mini-hyper-CVD can help to control the disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Relapsed/Refractory, B-cell Acute Lymphocytic Leukemia
Study phase:
Physician name:
Elias Jabbour
Department:
Leukemia
For general questions about clinical trials:
1-833-471-0966
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.